Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ANGION BIOMEDICA CORP.

(ANGN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/19/2021 11/22/2021 11/23/2021 11/24/2021 11/26/2021 Date
4.1(c) 4.05(c) 3.99(c) 3.98(c) 3.75(c) Last
102 096 120 005 128 628 112 951 117 651 Volume
-0.97% -1.22% -1.48% -0.25% -5.78% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 4,12 M - -
Net income 2021 - - -
Net Debt 2021 - - -
P/E ratio 2021 -
Yield 2021 -
Sales 2022 13,0 M - -
Net income 2022 - - -
Net Debt 2022 - - -
P/E ratio 2022 -
Yield 2022 -
Capitalization 112 M 112 M -
Capi. / Sales 2021 27,3x
Capi. / Sales 2022 8,67x
Nbr of Employees 72
Free-Float 60,3%
More Financials
Company
Angion Biomedica Corp. is a late-stage biopharmaceutical company. The Company focuses on discovery, development and commercialization of small molecule therapeutics to address acute organ injuries and fibrotic diseases. The CompanyÔÇÖs lead product candidate is ANG-3777. Its pipeline includes ANG-3070, rho kinase 2 (ROCK2), and CYP11B2. Its ANG-3777 is a hepatocyte growth factor (HGF) mimetic it is evaluating in... 
More about the company
All news about ANGION BIOMEDICA CORP.
11/12Angion Provides Corporate Update and Reports Third Quarter 2021 Financial Results - For..
PU
11/12ANGION BIOMEDICA CORP. Management's Discussion and Analysis of Financial Condition and..
AQ
11/12Angion Biomedica Corp. Reports Earnings Results for the Third Quarter and Nine Months E..
CI
11/12Earnings Flash (ANGN) ANGION BIOMEDICA Reports Q3 Loss $-0.53
MT
11/12Earnings Flash (ANGN) ANGION BIOMEDICA Reports Q3 Revenue $1.5M
MT
11/12Angion Provides Corporate Update and Reports Third Quarter 2021 Financial Results
AQ
11/09HC Wainwright Adjusts Angion Biomedica's Price Target to $50 From $100, Reiterates Buy ..
MT
11/04Angion Presents Multiple Posters on ANG-3070 at Kidney Week 2021, Including Preclinical..
AQ
11/02Angion to Participate in Upcoming Investment Conference
AQ
10/27Top Midday Decliners
MT
10/27Stifel Adjusts Price Target on Angion Biomedica to $15 from $40, Keeps Buy Rating
MT
10/27Oppenheimer Adjusts Angion Biomedica PT to $15 From $38, Maintains Outperform Rating
MT
10/27Wall Street Treads Water Pre-Bell, Consolidating After Dow, S&P Hit Fresh Record Highs
MT
10/27Top Premarket Decliners
MT
10/27Angion Biomedica Late-Stage Trial of Kidney Transplant Drug Fails to Meet Primary Endpo..
MT
More news
News in other languages on ANGION BIOMEDICA CORP.
11/12Earnings Flash (ANGN) ANGION BIOMEDICA annonce un chiffre d'affaires de 1,5 million de ..
10/27Wall Street fait du sur-place avant la cloche et consolide après que le Dow et le S&P a..
10/27L'essai de phase tardive d'Angion Biomedica sur un médicament pour la transplantation r..
10/27Angion Biomedica déclare que l'essai de phase avancée d'un médicament pour la transplan..
08/12Earnings Flash (ANGN) ANGION BIOMEDICA annonce un chiffre d'affaires de 540 000 $ pour ..
More news
Analyst Recommendations on ANGION BIOMEDICA CORP.
More recommendations
Chart ANGION BIOMEDICA CORP.
Duration : Period :
Angion Biomedica Corp. Technical Analysis Chart | ANGN | US03476J1079 | MarketScreener
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 3,75 $
Average target price 26,67 $
Spread / Average Target 611%
Managers and Directors
Jay R. Venkatesan President, Chief Executive Officer & Director
Greg S. Curhan Chief Financial Officer
Itzhak D. Goldberg Executive Chairman & Chief Scientific Officer
John F. Neylan Chief Medical Officer & Senior Vice President
Jennifer J. Rhodes Secretary, Chief Compliance Office & Senior VP
Sector and Competitors
1st jan.Capi. (M$)
ANGION BIOMEDICA CORP.0.00%112
MODERNA, INC.215.53%133 648
LONZA GROUP AG29.85%59 443
IQVIA HOLDINGS INC.46.26%50 064
SEAGEN INC.-3.22%30 994
CELLTRION, INC.-40.39%24 431